Practical management of patients treated with alpha interferon

Area of Science:

• Hepatology
• Immunology
• Endocrinology

Background:

• Interferon alpha is a treatment for chronic hepatitis.
• Its use is associated with known side effects that require careful management.
• Monitoring for potential complications is essential during therapy.

Purpose of the Study:

• To review the spectrum of side effects associated with interferon alpha therapy.
• To highlight the importance of vigilant patient monitoring during interferon treatment.
• To inform clinical decisions regarding the continuation or cessation of interferon therapy.

Main Methods:

• Review of clinical manifestations and biochemical changes during interferon alpha therapy.
• Analysis of reported adverse events, including autoantibody production, thyroid dysfunction, liver disease exacerbation, neuropsychological disturbances, and dermatological conditions.
• Emphasis on diagnostic markers such as antithyroid antibodies and TSH levels.

Main Results:

• Interferon therapy can lead to the appearance of autoantibodies, often without symptoms.
• Thyroid dysfunction (dysthyroidism) requires monitoring of antithyroid antibodies and TSH.
• Potential for liver disease exacerbation, neuropsychological disturbances (including depression), and worsening of skin conditions like psoriasis and lichen planus.
• Some side effects can be life-threatening, necessitating careful risk-benefit assessment.

Conclusions:

• Interferon alpha therapy necessitates comprehensive monitoring for a wide range of potential side effects.
• Early detection and management of adverse events are critical for patient safety.
• Therapeutic decisions should balance treatment response with the severity of interferon-induced side effects.